The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (N-acetylcysteine 600 mg/day) in a dry AMD patient with large drusen.
Participants will divided in to three groups.
* Participants who were already taking low dose antiplatelet medications. * Participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator * Participants does not use any medications.
Dry AMD with at least 1 large drusen. According to the AREDS study, large drusen have a size of more than 125 micron.
Patients can evaluate SD-OCT (Spectral domain optical coherence tomography), OCT angiography, and best-corrected visual acuity.
Age range: 50-85 years
Patients who have previously used antiplatelet drugs.
Patient with advanced AMD, such as geographic atrophy, neovascular complications (choroidal neovascularization)
Patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema.
Patient with a history of intravitreal anti-VEGF injection or macular laser.
Patient using SSRIs, SNRIs, azole, NSAIDs, dual antiplatelet, anticoagulant medications.